DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Thrombate III (Antithrombin III) - Published Studies


Thrombate III Related Published Studies

Well-designed clinical trials related to Thrombate III (Antithrombin III)

Antithrombin III for critically ill patients. [2008.07.16]

Antithrombin for respiratory distress syndrome in preterm infants. [2006.10.18]

Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. [2006.05]

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. [2006.02]

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. [2006.01]

Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. [2005.08]

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. [2005.07]

Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. [2004.09]

[Dynamics of thrombin-antithrombin-III complex (TAT-III) and prothrombin fragments F1 + 2 during labour with and without aprotinin administration] [2004.06]

Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants? [2003]

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. [2002.08]

The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. [2002.06]

Antithrombin III in Sepsis. New evidences and open questions. [2002.05]

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. [2001.10.17]

Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. [2001.01]

Clinical trial results with antithrombin III in sepsis. [2000.09]

Technology evaluation: transgenic antithrombin III (rhAT-III), Genzyme Transgenics. [2000.06]

Antithrombin III in patients with severe sepsis: a pharmacokinetic study. [2000.06]

Antithrombin III and local serum application: adjuvant therapy in peritonitis. [2000.04]

[The effect of antithrombin iii concentrations during cardiopulmonary surgery] [2000.01]

The role of antithrombin III in the perioperative management of the patient with unstable angina. [1999.12]

Gabexate mesilate and antithrombin III for intraoperative anticoagulation in heparin pretreated patients. [1999.09]

High-dose antithrombin III treatment of severely injured patients: results of a prospective study. [1998.11]

Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. [1998.08]

A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. [1998.08]

Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. [1998.07]

Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. [1998.07]

Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. [1998.04]

Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium. [1998.03.02]

Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. [1998.03]

Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement. [1998.03]

A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. [1998]

Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. [1997.11]

[D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders] [1997.08]

Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study. [1997.03]

The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen--relationship with physiological variables and establishment of reference ranges. [1996.08]

Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. [1995.12]

Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate. [1995.11]

Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: evidence against a cause-effect relationship. [1995.03]

Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial. [1994.11]

Use of antithrombin III in critical patients. [1994.11]

Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. [1994.09]

Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. [1994.05]

Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates. [1994.04.15]

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. [1993.09]

Controlled trial of antithrombin III supplementation in fulminant hepatic failure. [1993.03]

Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. [1993.02.15]

Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. [1992.12.01]

Effect of antithrombin concentrate on haemostatic variables in critically ill patients. [1992.11]

Fibrinogen and antithrombin III blood levels fluctuations during isoniazid or isoniazid plus rifampicin administration. [1992.08]

Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. [1992.02]

Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. [1991.08]

A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. [1991.06]

Oral contraceptives and antithrombin III: variations by dosage and ABO blood group. [1991.06]

Coagulation and fibrinolysis in orthotopic liver transplantation: role of the recipient's disease and use of antithrombin III concentrates. S. Orsola Working Group on Liver Transplantation. [1991]

Levels of thrombin--antithrombin-III complex and factor VIII activity in relation to post-operative deep vein thrombosis and influence of prophylaxis with a low-molecular-weight heparin. [1990.10]

Prevention of venous thrombosis after total knee arthroplasty. Comparison of antithrombin III and low-dose heparin with dextran. [1990.08]

Fluctuation of thrombin-antithrombin III complex in patients with acute myocardial infarction: influence of low-dose heparin administration. [1990]

Thrombin-antithrombin III complexes in the prediction of deep vein thrombosis following total hip replacement. [1989.12.29]

Antithrombin III/low-dose heparin in the prevention of deep-vein thrombosis after total knee arthroplasty. A preliminary report. [1989.11]

Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement. [1989.09.11]

Prevention of venous thrombosis after total hip arthroplasty. Antithrombin III and low-dose heparin compared with dextran 40. [1989.03]

Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment. [1989.02]

[Use of antithrombin III concentrates] [1989]

Antithrombin III and protein C in stable angina pectoris--influence of dietary supplementation with polyunsaturated fatty acids. [1988.09]

Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. [1988.01]

Virus safety of a pasteurized antithrombin III concentrate. Preclinical and clinical data. [1987.07]

Well-designed clinical trials possibly related to Thrombate III (Antithrombin III)

Evaluation of hemostatic factors in patients undergoing major hepatic resection and other major abdominal surgeries. [2011.09]

Evidence based evaluation of immuno-coagulatory interventions in critical care. [2011.09]

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. [2011.06.06]

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. [2011.06.01]

Cardiotomy suction, but not open venous reservoirs, activates coagulofibrinolysis in coronary artery surgery. [2011.05]

Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. [2011.02]

Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. [2011.01]

Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. [2010.11]

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. [2010.07]

The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. [2010.07]

[Comparison of hemostatic markers under different techniques for anesthesia-analgesia in total hip or knee replacement] [2010.06]

Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting. [2010.04]

Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. [2010.01]

Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. [2010]

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. [2009.11.15]

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. [2009.07]

The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. [2009.04]

Pulsatile perfusion with intra-aortic balloon pumping ameliorates whole body response to cardiopulmonary bypass in the elderly. [2009.03]

Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization. [2009.02]

Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study. [2009.02]

Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. [2009]

Impact of non-di-(2-ethylhexyl)phthalate cardiopulmonary bypass tubes on inflammatory cytokines and coagulation-fibrinolysis systems during cardiopulmonary bypass. [2009]

Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. [2008.11]

Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. [2008.10.01]

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. [2008.09.15]

Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. [2008.09]

Heparin-coated extracorporeal circulation in combination with low dose systemic heparinization reduces early postoperative blood loss in cardiac surgery. [2008.04]

A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans. [2008.02]

Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women. [2008.02]

Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study. [2008]

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation. [2008]

[Determination concentrations of tissue factor pathway inhibitor and their changes during estrogen replacement therapy] [2007.10]

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. [2007.09.20]

Coagulation status and the presence of postoperative deep vein thrombosis in patients undergoing laparoscopic cholecystectomy. [2007.09]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012